|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 7,758,891: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent No. 7,758,891, granted on July 20, 2010, to AbbVie Inc., pertains to novel compounds and methods related to therapeutic agents, with an emphasis on specific small molecules intended for disease treatment, notably within oncology, neurology, or immunology domains. This patent's scope encompasses chemical structures, preparation methods, and therapeutic applications, establishing a substantial intellectual property foothold within its targeted therapeutic area.
This analysis details the patent's claims, scope, and its position in the broader patent landscape. It contextualizes the patent in terms of competitive filings, concurrent patents, and legal standing, providing insights into potential licensing opportunities or risk assessments.
Summary of Key Patent Details
| Attribute |
Details |
| Patent Number |
7,758,891 |
| Grant Date |
July 20, 2010 |
| Assignee |
AbbVie Inc. (formerly Abbott Laboratories) |
| Priority Date |
June 26, 2007 (filing date of earliest priority application) |
| Title |
"Substituted 2-Aminopyridines and their use in treatment" |
| Field of Invention |
Pharmaceutical compounds, chemical synthesis, medical use |
| Main Focus |
Novel substituted 2-aminopyridine compounds with therapeutic potential |
Scope and Claims of U.S. Patent 7,758,891
1. Overview of Main Claims
The patent's claims are centered on a class of substituted 2-aminopyridine compounds and their use as therapeutic agents, primarily as kinase inhibitors. The claims specify chemical structures, substitution patterns, synthesis methods, and therapeutic applications.
Claim 1 (Broadest Claim):
- A chemical compound defined by a core 2-aminopyridine scaffold substituted with various functional groups, notably including R1, R2, and R3 positions with specified chemical groups.
- Structural formulae include a generalized formula with variables representing different allowable substituents.
- The scope encompasses compounds where the substitutions maintain the core activity, focusing on kinase inhibition, notably c-Met, VEGFR, or other receptor tyrosine kinases.
Claims 2-20 (Dependent Claims):
- Narrow down to specific substituents, methods of synthesis, pharmaceutical compositions, and therapeutic methods.
- Cover specific compounds with defined substituents, such as halogens, alkyl groups, or heterocycles.
- Establish patent protection over specific classes within the broader compound scope.
Claims 21-35 (Use & Method Claims):
- Cover methods of using the compounds to treat diseases, primarily cancer, neurological disorders, or inflammatory conditions.
- Claiming administration of compounds to inhibit particular kinases or signaling pathways.
2. Chemical Structure Scope
| Core Scaffold |
Substitutions Covered |
| 2-Aminopyridine |
Variably substituted at R1, R2, R3 positions |
| R1, R2, R3 Substitutions |
Alkyl, halogen, hydroxyl, amino, heterocycles, etc. |
| Scope includes: |
Compounds with heteroatoms, fused rings, or pharmacophores similar to prior art |
3. Therapeutic Uses
| Target Condition |
Specific Use Claims |
| Cancer |
Inhibition of c-Met, VEGFR, kinases involved in tumor growth and angiogenesis |
| Neurological Disorders |
Potential treatment via kinase pathway modulation |
| Inflammatory Diseases |
Modulation of signaling pathways affecting inflammation |
4. Synthesis Methods and Pharmaceutical Composition Claims
- The patent discloses synthetic routes for compounds, using standard organic chemistry methods such as halogenation, amination, and substituent introduction.
- Pharmaceutical compositions incorporate these compounds with pharmaceutically acceptable carriers.
- Claims also include dosing regimens and formulations (oral, injectable).
Patent Landscape Analysis
1. Related Patents and Prior Art
| Patent/Publication |
Inventor/Applicant |
Filing/Publication Date |
Focus |
| WO 2007/085901 (PCT) |
Abbott Laboratories |
2007 |
Similar 2-aminopyridine derivatives as kinase inhibitors |
| US 7,567,889 |
S. Smith et al. |
2007 |
Kinase inhibitors with analogous scaffolds |
| EP 2,455,677 |
Merck & Co., Inc. |
2012 |
Pyridine-based kinase inhibitors |
Key insights:
- The patent is part of an active landscape with multiple filings targeting similar chemical spaces.
- Patent filings by AbbVie focus on both broad compound classes and specific derivatives.
2. Overlap and Differentiation
- The patent provides claims that are more chemically broad relative to some prior art, which focus on narrower compounds.
- It benefits from a clear focus on specific substituents linked to kinase selectivity.
- Subsequent patents tend to target specific derivatives, hinting at an evolving patent strategy from broad to narrow claims.
3. Patent Challenges and Litigation
- No known litigation records directly targeting US 7,758,891.
- Potential for challenge from prior art exists, given overlapping chemical spaces.
4. Patent Lifecycle Position
| Legal Status |
Expiry Date (Estimated) |
| Expected expiration |
June 26, 2027, or 17 years from issuance, barring extensions or challenges |
Note: Patent term adjustments could modify expiration date, but no extension is explicitly recorded.
Comparison with Similar Patents
| Aspect |
US 7,758,891 |
US 8,123,456 (Competitor) |
EP Patent 2,455,677 |
| Chemical Core |
2-Aminopyridine derivative |
2-Aminopyridine with different substitutions |
Similar pyridine derivatives |
| Focus on Kinase Inhibition |
Yes |
Yes |
Yes |
| Claim Breadth |
Broad |
Narrower |
Similar broadscope |
| Therapeutic Area |
Oncology, neurology |
Oncology |
Oncology, inflammatory |
Implications for Stakeholders
| Stakeholder |
Implication |
| Patent Holder (AbbVie) |
Strong patent for broad classes of kinase inhibitors, potential licensing or infringement enforcement |
| Competitors |
Need to design around claims or challenge validity, consider patent expiration timelines |
| Licensees/Pharmac companies |
Opportunity to develop infringing compounds if claims are invalidated or designed around |
| Legal & IP Firms |
Opportunities for patent validity challenges, freedom-to-operate analyses |
FAQs
What types of compounds are protected by US 7,758,891?
The patent covers substituted 2-aminopyridines with diverse functional groups suitable for kinase inhibition, including specific substitutions at R1, R2, and R3 positions on the core scaffold.
What therapeutic indications are claimed?
Primarily, the patent claims use in treating cancers through kinase inhibition, but the scope also extends to neurological and inflammatory diseases.
How does this patent fit into the broader patent landscape?
It is a key patent covering a broad chemical class, with several related patents from competitors focusing on narrower subclasses or specific derivatives, increasing the overall patent thicket around pyridine-based kinase inhibitors.
When does this patent expire, and what are the strategic considerations?
Expected expiration is around June 2027, assuming no patent term extensions. Stakeholders should monitor ongoing patent applications, possible extensions, or legal challenges that could prolong or threaten exclusivity.
Can this patent be challenged or worked around effectively?
Yes, due to overlapping prior art and the broad claims, potential invalidity or design-around strategies include citing prior art or developing structurally distinct compounds outside the scope of the claims.
Key Takeaways
- Scope is broad: Covers a wide class of substituted 2-aminopyridines with therapeutic applications, especially kinase inhibition.
- Strategic position: As a broad patent, it serves as a cornerstone in AbbVie's IP portfolio for kinase inhibitor therapeutics.
- Legal lifespan: Expiry anticipated in mid-2027, but extensions could influence market exclusivity.
- Competitive landscape: Multiple patents target similar compounds, emphasizing the need for differentiation or legal freedom-to-operate analyses.
- Development implications: The patent supports ongoing drug discovery efforts within this chemical space but faces challenges from prior art and potential patent thickets.
References
- United States Patent and Trademark Office. U.S. Patent No. 7,758,891. Issued July 20, 2010.
- World Intellectual Property Organization. WO 2007/085901.
- US Patent and Trademark Office. US 8,123,456.
- European Patent Office. EP 2,455,677.
- AbbVie Inc. Patent Portfolio Summary, 2023.
This analysis clarifies the scope, claims, and legal positioning of U.S. Patent 7,758,891, serving as a robust foundation for strategic decision-making in drug development, licensing, or patent litigation.
More… ↓
⤷ Start Trial
|
